Dr. Charles Reay Mackay named chief scientific officer of Pfizer Inc.
“I am privileged to be joining a world-class team of scientists that has made an important contribution to the field of Inflammation and Immunology research,” Mackay said. “We have an important opportunity to advance a robust pipeline of novel agents that target the root cause of inflammation at a molecular level across several disease areas such as inflammatory bowel disease (IBD), lupus, psoriasis, Chronic Obstructive Pulmonary Disorder and other chronic diseases. We will also pursue other novel approaches that could help transform the way inflammatory diseases are treated.”
Mackay’s direct supervisor will be Jose-Carlos Gutiérrez-Ramos, Ph.D., the group's vice president of BioTherapeutics Research and Development.
“Professor Mackay’s research has focused on understanding the fundamental mechanisms that regulate the immune system, developing new monoclonal antibody treatments for inflammation and exploring strategies to prevent inflammatory diseases through gut microbe/epithelial barrier modulation,” Gutiérrez-Ramos said. “Professor Mackay brings to Pfizer a unique combination of scientific expertise, academic credentials and entrepreneurial spirit. His deep commitment to drug discovery and his unique skill set will help advance Pfizer’s position as a global leader in inflammation and a collaborator of choice within the Cambridge community and beyond.”
Mackay will be based at the research and development hub for Pfizer in Cambridge, Mass.